BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 24797362)

  • 1. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
    Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
    Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
    Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
    Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
    Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
    Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
    Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
    Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RNA helicase DDX5 cooperates with EHMT2 to sustain alveolar rhabdomyosarcoma growth.
    Gualtieri A; Bianconi V; Renzini A; Pieroni L; Licursi V; Mozzetta C
    Cell Rep; 2022 Aug; 40(9):111267. PubMed ID: 36044855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo.
    Raimondi L; Ciarapica R; De Salvo M; Verginelli F; Gueguen M; Martini C; De Sio L; Cortese G; Locatelli M; Dang TP; Carlesso N; Miele L; Stifani S; Limon I; Locatelli F; Rota R
    Cell Death Differ; 2012 May; 19(5):871-81. PubMed ID: 22117196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
    Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J
    Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
    Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
    Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma.
    Saini M; Verma A; Mathew SJ
    Cell Death Dis; 2018 Feb; 9(2):237. PubMed ID: 29445192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma.
    Annavarapu SR; Cialfi S; Dominici C; Kokai GK; Uccini S; Ceccarelli S; McDowell HP; Helliwell TR
    Lab Invest; 2013 Oct; 93(10):1090-9. PubMed ID: 23999248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
    Bois PR; Izeradjene K; Houghton PJ; Cleveland JL; Houghton JA; Grosveld GC
    J Cell Biol; 2005 Sep; 170(6):903-12. PubMed ID: 16157701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor acts in an autocrine manner in rhabdomyosarcoma cell lines and can be inhibited with all-trans-retinoic acid.
    Gee MF; Tsuchida R; Eichler-Jonsson C; Das B; Baruchel S; Malkin D
    Oncogene; 2005 Dec; 24(54):8025-37. PubMed ID: 16116481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.